Here, we have used a vaccine platform consisting of a cationic liposome containing a recombinant trimeric SARS-CoV-2 spike protein to induce robust T-follicular helper cell and humoral responses [14], adjuvanted with CpG oligonucleotides to boost mucosal IgA antibody production [15] and Th1 cellular immunity, in a transgenic mouse model (K18-hACE2) of COVID-19 [16], aiming to obtain humoral and cellular effector and memory immune responses as depicted in the graphic illustration (Figure 1). Here, CD79A is linked to COVID-19.